BioScrip, Inc. (BIOS): Price and Financial Metrics
BIOS Price/Volume Stats
| Current price | $10.81 | 52-week high | $11.68 |
| Prev. close | $10.82 | 52-week low | $10.02 |
| Day low | $10.81 | Volume | 25,000 |
| Day high | $10.81 | Avg. volume | 130,867 |
| 50-day MA | $10.71 | Dividend yield | N/A |
| 200-day MA | $10.44 | Market Cap | 209.36M |
BIOS Stock Price Chart Interactive Chart >
BioScrip, Inc. (BIOS) Company Bio
BioScrip, Inc. provides home infusion and other home care services, and pharmacy benefit management services in the United States. It operates in two segments, Infusion Services and PBM Services. The company was founded in 1993 and is based in Eden Prairie, Minnesota.
Latest BIOS News From Around the Web
Below are the latest news stories about BIOPLUS ACQUISITION CORP that investors may wish to consider to help them evaluate BIOS as an investment opportunity.
Avertix Partners with Institute on Implantable Heart Attack Detection SystemBy Daniella Parra Avertix Medical said it was collaborating with the Heart & Rhythm Institute of Trinity to bring an FDA-approved implantable heart attack detection and warning system to patients with high-risk coronary disease, it said. The implant, called the “Guardian System,” is designed to capture cardiac signals from inside the heart in order to […] |
Heart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient MonitoringThe Avertix Guardian™ System, the first and only FDA approved implantable heart attack warning system, now available at the Heart & Rhythm Institute of Trinity, extending their commitment to redefining cardiac care in the Tampa, FL area Dr. Luis R. Annoni-Suau, MD, FACC and Dr. Carlos J. Bayron successfully performed the first two Guardian implants at the Heart and Rhythm Institute of Trinity EATONTOWN, N.J. and TRINITY, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or |
Avertix Medical Welcomes Renown Cardiologist to Board of DirectorsBy Daniella Parra Avertix Medical announced that Professor Ian Meredith AM will join the Board of Directors, bringing extensive experience as a renowned interventional cardiologist and global medical executive, the company said. “Avertix has a meaningful product that holds the potential to empower patients at a time of great anxiety and uncertainty in their lives,” […] |
Renown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of DirectorsRecently served as Boston Scientific Executive Vice President and Global Chief Medical Officer Professor Meredith brings to Avertix over 35 years of cardiology experience and commitment to advancing cardiac care EATONTOWN, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a healthcare technology company commercializing the first and only FDA-approved heart attack warning system to improve long-term managemen |
FDA-Approved Implantable Heart Attack Detection System Introduced by Avertix Medical and AdventHealth OrlandoBy Daniella Parra Avertix Medical and AdventHealth Orlando have introduced the Guardian™ System, an FDA-approved implantable heart attack detection and warning system. “I believe the Guardian System introduces a significant advancement in cardiac care, potentially transforming how we detect heart attacks,” Dr. Usman Siddiqui, medical director of electrophysiology at AdventHealth’s hospitals, said. “I am excited to […] |
BIOS Price Returns
| 1-mo | 0.84% |
| 3-mo | 2.08% |
| 6-mo | 3.74% |
| 1-year | 7.78% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Continue Researching BIOS
Here are a few links from around the web to help you further your research on NA's stock as an investment opportunity:NA (BIOS) Stock Price | Nasdaq
NA (BIOS) Stock Quote, History and News - Yahoo Finance
NA (BIOS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...